ANVS401 Improves Cognition in Alzheimer’s and Parkinson’s, Data Show

ANVS401 Improves Cognition in Alzheimer’s and Parkinson’s, Data Show

296353

ANVS401 Improves Cognition in Alzheimer’s and Parkinson’s, Data Show

Annovis Bio’s oral therapy ANVS401 (also known as Posiphen) led to significant improvements in cognition in patients with Alzheimer’s disease, according to data from the first patient group in a Phase 2a study. The improvements were also observed in patients with Parkinson’s disease enrolled in the study. “The results from the first cohort of 14 [Alzheimer’s] and 14 [Parkinson’s] patients, show that the drug is effective in both diseases,” Maria L. Maccecchini, PhD, CEO of…

You must be logged in to read/download the full post.